268 related articles for article (PubMed ID: 19837909)
1. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.
Peacock M; Bilezikian JP; Klassen PS; Guo MD; Turner SA; Shoback D
J Clin Endocrinol Metab; 2005 Jan; 90(1):135-41. PubMed ID: 15522938
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
7. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP
Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527
[TBL] [Abstract][Full Text] [Related]
8. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
[TBL] [Abstract][Full Text] [Related]
9. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
Shoback DM; Bilezikian JP; Turner SA; McCary LC; Guo MD; Peacock M
J Clin Endocrinol Metab; 2003 Dec; 88(12):5644-9. PubMed ID: 14671147
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
Norman J; Lopez J; Politz D
Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.
Marcocci C; Chanson P; Shoback D; Bilezikian J; Fernandez-Cruz L; Orgiazzi J; Henzen C; Cheng S; Sterling LR; Lu J; Peacock M
J Clin Endocrinol Metab; 2009 Aug; 94(8):2766-72. PubMed ID: 19470620
[TBL] [Abstract][Full Text] [Related]
13. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
[TBL] [Abstract][Full Text] [Related]
15. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
17. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
Martin KJ; Jüppner H; Sherrard DJ; Goodman WG; Kaplan MR; Nassar G; Campbell P; Curzi M; Charytan C; McCary LC; Guo MD; Turner SA; Bushinsky DA
Kidney Int; 2005 Sep; 68(3):1236-43. PubMed ID: 16105056
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial.
Rolighed L; Rejnmark L; Sikjaer T; Heickendorff L; Vestergaard P; Mosekilde L; Christiansen P
J Clin Endocrinol Metab; 2014 Mar; 99(3):1072-80. PubMed ID: 24423366
[TBL] [Abstract][Full Text] [Related]
20. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
